News

Euclid Vision Welcomes Specialty Eyecare Professional to Commercial Team

Euclid Vision Corp., a global leader in specialty contact lenses and proactive myopia management initiatives, is pleased to announce the continued expansion of its U.S. sales team with the addition of Jon R. Hudson, ABOC, NCLEC, who has joined the company as account executive for Texas, and Central and Southern U.S. territories. Jon brings 24 years of experience in the eye care industry to his new role.

“We are all very excited to have Jon join our commercial team. The addition of Jon to the U.S. sales force will enable Euclid and Visionary Optics to assist more eye care professionals (ECPs) in providing best-in-class services to more patients, and reinforces our commitment to ECPs and their patients,” said David Bland, Euclid Vision, vice president of sales.

Jon started his career in the eye care industry as a lab technician and optician in both retail and independent eye care practices and followed that by managing independent eye care practices prior to branching off on his own as a practice management consultant. His time with independent practices was focused primarily on maximizing per patient revenue, including the implementation of myopia management programs and initiatives designed to add scleral lenses as a treatment option. Myopia is the leading cause of visual impairment in children worldwide, and its incidence and prevalence are on the rise, with estimates suggesting that more than half of the world’s population will be myopic by 2050. Jon’s passion for myopia management led to his employment with CooperVision Specialty EyeCare, where he held various roles over the course of six years. His primary focus involved development of practice management initiatives for myopia management and training the sales team on implementation of those programs.

Euclid Vision acquired Visionary Optics, a specialty scleral contact lens design and manufacturing pioneer, in 2022. The union of these two companies increases each establishment’s ability to provide comprehensive specialty contact lens care to more patients globally.  “As Euclid Vision and Visionary Optics focus on assisting more ECPs with their efforts to deliver best-in-class specialty contact lens services, in areas such as orthokeratology, scleral, and keratoconus management, Jon’s expansive experience in all sectors of eye care is the perfect fit for our commercial team and the customers we serve in this geographic region,” said Bland.

 

Learn more here.

Recent News

06/11/2026

Adial Pharmaceuticals Announces Acquisition of Azora Therapeutics and up to $64 Million Financing

Adial Pharmaceuticals, Inc. (Nasdaq: ADIL) (“Adial” or the “Company”) today announced that it has acquired Azora Therapeutics, Inc. (“Azora”), a biopharmaceutical company developing treatments for serious inflammatory diseases. The acquisition brings Azora’s lead asset AT177, a proprietary colon‑targeted aryl hydrocarbon receptor (AhR) agonist designed to enable localized activation with limited systemic exposure, into Adial’s pipeline.

06/11/2026

Luna Labs Launches 3 Waves Venture Spinout to Commercialize Advanced Vestibular Stimulation Technology

Luna Labs today announced the launch of 3 Waves, Inc. (“3Waves”), a dual-use spinout company that was established to commercialize advanced virtual and mixed reality technologies for defense, commercial simulation, and medical applications. As part of the spinout, 3Waves and Mayo Clinic executed an exclusive license to support the development of next-generation vestibular stimulation systems

06/02/2026

TearSolutions Receives FDA Orphan Drug and Fast Track Designations for Lacripep® in Neurotrophic Keratitis and Initiates Phase 2 Clinical Trial with First Patients Dosed

TearSolutions, Inc. (“TearSolutions”), a clinical-stage biotechnology company developing novel ophthalmic therapeutics, today announced receiving Food and Drug Administration (FDA) Orphan Drug (ODD) and Fast Track Designations for Lacripep in Neurotrophic Keratitis (NK) and initiating a Phase 2 clinical trial with first patients dosed. The FDA’s ODD provides incentives, including tax credits for clinical testing and